GlycA and GlycB as Inflammatory Markers in Chronic Heart Failure.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 Oct 2022
15 Oct 2022
Historique:
received:
21
04
2022
revised:
27
06
2022
accepted:
05
07
2022
pubmed:
26
8
2022
medline:
15
9
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
The role of inflammation in heart failure (HF) has been extensively described, but it is uncertain whether inflammation exerts a different prognostic influence according to etiology. We aimed to examine the inflammatory state in chronic HF by measuring N-acetylglucosamine/galactosamine (GlycA) and sialic acid (GlycB), evolving proton nuclear magnetic resonance biomarkers of systemic inflammation, and explore their prognostic value in patients with chronic HF. The primary end point was a composite of all-cause death and HF readmission. A total of 429 patients were included. GlycB correlated with interleukin-1 receptor-like 1 in the whole cohort (r
Identifiants
pubmed: 36008162
pii: S0002-9149(22)00749-4
doi: 10.1016/j.amjcard.2022.07.019
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-86Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures Dr. Amigó is a stock owner of Biosfer Teslab, the company analyzing the glycoprotein profiling reported in the manuscript. The remaining authors have no conflicts of interest to declare. Informed consent. Informed consent was obtained from all subjects included in this study.